Effect of roxadustat on iron metabolism in patients with peritoneal dialysis: a real-world 24-week study.
Eur J Med Res
; 28(1): 489, 2023 Nov 07.
Article
em En
| MEDLINE
| ID: mdl-37936193
ABSTRACT
BACKGROUND:
Roxadustat is an oral hypoxia inducing factor-prolyl hydroxylase inhibitor (HIF-PHI) that regulates iron metabolism in patients with chronic kidney disease (CKD) primarily by reducing hepcidin levels and mobilizing internal iron stores. More data are needed to demonstrate the efficacy of roxadustat in regulating iron metabolism in patients with peritoneal dialysis (PD) compared with erythropoiesis stimulating agents (ESAs).METHODS:
This prospective cohort study enrolled PD patients with a mean hemoglobin level of 60-100 g/L. All subjects were randomized into two groups at a ratio of 21 the roxadustat group (106 cases), and the ESA group (53 cases). The primary endpoint was the change in the iron biomarker levels and the proportion of patients with absolute iron deficiency and functional iron deficiency.RESULTS:
Compared with ESAs, roxadustat significantly decreased hepcidin level (difference, - 20.09 ng/mL; 95% CI, - 30.26 to - 9.92), attenuated the increase in serum soluble transferrin receptor (sTFR) level (difference, - 7.87 nmol/L; 95% CI, - 12.11 to - 3.64), and reduced the proportion of patients with functional iron deficiency (roxadustat, 11.43%; ESA, 33.33%). There was no significant difference in safety of the two groups over the duration of the study.CONCLUSIONS:
Compared with ESA group, roxadustat group showed significant differences in all iron biomarker levels except serum ferritin (sFt) and transferrin saturation (TSAT). These results suggest that roxadustat was superior to ESAs as a therapy for iron metabolism in PD patients. TRIAL REGISTRATION This study completed Chinese Clinical Trial Registration on March 4, 2022 (registration number ChiCTR2200057231).Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Deficiências de Ferro
/
Glicina
/
Isoquinolinas
Limite:
Humans
Idioma:
En
Ano de publicação:
2023
Tipo de documento:
Article